Cargando…
P1634: EFFICACY AND SAFETY OF ELTROMBOPAG IN THE TREATMENT OF CHRONIC HEPATITIS B VIRUS INFECTION PATIENTS WITH THROMBOCYTOPENIA(HBV-TP): A PROSPECTIVE, MULTI-CENTER, SINGLE ARM, PHASE II TRAIL
Autores principales: | Chen, Y., Huang, Y., Lai, Y., Peng, J., Zhou, Z., Zhou, H., Zhou, R., Yang, R., Zhang, L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430737/ http://dx.doi.org/10.1097/01.HS9.0000849392.16448.ae |
Ejemplares similares
-
Considerations in the Management of Hepatitis C Virus-related Thrombocytopenia with Eltrombopag
por: Danish, Fazal A., et al.
Publicado: (2010) -
Eltrombopag plus cyclosporine in refractory immune thrombocytopenia: a single-center study
por: Hong, Yilei, et al.
Publicado: (2023) -
The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia
por: Danish, Fazal-i-Akbar, et al.
Publicado: (2013) -
Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia
por: Elbedewy, Tamer A, et al.
Publicado: (2019) -
Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial
por: Zaninetti, Carlo, et al.
Publicado: (2020)